CTLA4 and glioma: A variety of clinical trials targeting programmed death (PD)-1/PD-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen (CTLA)-4 have been investigated in patients with glioma to promote the robust antitumor T cell response [7].